Filtered By:
Therapy: Chemotherapy

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 93387 results found since Jan 2013.

Cutaneous T‐cell lymphoma: 2014 Update on diagnosis, risk‐stratification, and management
Disease overview: Cutaneous T‐cell lymphomas are a heterogenous group of T‐cell lymphoproliferative disorders involving the skin, the majority of which may be classified as Mycosis Fungoides (MF) or Sézary Syndrome (SS). Diagnosis: The diagnosis of MF or SS requires the integration of clinical and histopathologic data. Risk‐adapted therapy: TNMB (tumor, node, metastasis, and blood) staging remains the most important prognostic factor in MF/SS and forms the basis for a “risk‐adapted,” multidisciplinary approach to treatment. For patients with disease limited to the skin, expectant management or skin‐directed ...
Source: American Journal of Hematology - July 14, 2014 Category: Hematology Authors: Ryan A. Wilcox Tags: A Continuing Medical Education Series Source Type: research

Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2,388 health care providers
Conclusions This survey of health care providers uncovered key barriers and educational needs relevant to the management of CINV. The findings from this survey can be used to develop educational initiatives focused on improving the care of cancer patients at risk for or suffering from CINV.
Source: Supportive Care in Cancer - December 17, 2014 Category: Cancer & Oncology Source Type: research

Exam 2: Low Level of Hepatitis B Virus Screening Among Patients Receiving Chemotherapy
Source: Clinical Gastroenterology and Hepatology - March 15, 2015 Category: Gastroenterology Tags: Continuing Medical Education (CME) Activities Source Type: research

Mantle Cell Lymphoma: 2015 Update on Diagnosis, Risk‐Stratification and Clinical Management
This article is protected by copyright. All rights reserved.
Source: American Journal of Hematology - June 23, 2015 Category: Hematology Authors: Julie M. Vose Tags: Annual Clinical Updates in Hematological Malignancies: A Continuing Medical Education Series Source Type: research

Mantle cell lymphoma: 2017 update on diagnosis, risk ‐stratification, and clinical management
Abstract Disease OverviewMantle cell lymphoma (MCL) is a non‐Hodgkin lymphoma characterized by involvement of the lymph nodes, spleen, blood and bone marrow with a short remission duration to standard therapies and a median overall survival (OS) of 4‐5 years. DiagnosisDiagnosis is based on lymph node, bone marrow, or tissue morphology of centrocytic lymphocytes, small cell type, or blastoid variant cells. A chromosomal translocation t (11:14) is the molecular hallmark of MCL, resulting in the overexpression of cyclin D1. Cyclin D1 is detected by immunohistochemistry in 98% of cases. The absence of SOX‐11 or a low Ki...
Source: American Journal of Hematology - July 12, 2017 Category: Hematology Authors: Julie M. Vose Tags: ANNUAL CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES: A CONTINUING MEDICAL EDUCATION SERIES Source Type: research

Therapeutic Patterns and Barriers to the Treatment of Advanced Prostate  Cancer: A Survey of Academic and Community Urologists in the United States
Conclusions Similarities and differences were observed between community and academic urologists regarding the treatment of patients with metastatic castration resistant prostate cancer and barriers to treatment. Understanding these comparisons may assist in developing educational activities to improve urologist knowledge and, ultimately, patient care in metastatic castration resistant prostate cancer.
Source: Urology Practice - December 28, 2017 Category: Urology & Nephrology Source Type: research

How to Diagnose and Treat Breast Implant–Associated Anaplastic Large Cell Lymphoma
Learning Objectives: After reading this article, the participant should be able to: 1. Describe the diagnostic criteria for breast implant–associated (BIA) anaplastic large cell lymphoma (ALCL). 2. Appropriately evaluate a patient with suspected BIA-ALCL, including appropriate imaging, laboratory tests, and pathologic evaluation. 3. Understand the operative treatment of BIA-ALCL, and indications for systemic chemotherapy and/or radiation therapy in advanced disease. 4. Understand treatment outcomes and prognosis based on stage of disease. Summary: The goal of this continuing medical education module is to present th...
Source: Plastic and Reconstructive Surgery - March 30, 2018 Category: Cosmetic Surgery Tags: CME Source Type: research

Reply to: “Cutaneous squamous cell carcinoma progression during imiquimod treatment”
To the Editor: We appreciate the observation made by Dika et  al about cutaneous squamous cell carcinoma (cSCC) progression during imiquimod treatment.1 These cases emphasize what we describe in part II of our continuing medical education (CME) article–that topical chemotherapy agents should be limited to the treatment of actinic keratoses and squamous cel l carcinoma in situ and are only Food and Drug Administration–approved for use on actinic keratoses.2 As stated in the CME article, our preferred treatment choice for widespread actinic damage is topical 5-fluorouracil, as imiquimod is not practical for application ...
Source: Journal of the American Academy of Dermatology - March 26, 2018 Category: Dermatology Authors: Syril Keena T. Que, Fiona O. Zwald, Chrysalyne D. Schmults Tags: JAAD online Source Type: research

Hair disorders in cancer survivors
With increasing survival rates across all cancers, survivors represent a growing population that is frequently affected by persistent or permanent hair growth disorders as a result of systemic therapies, radiotherapy, surgical procedures, and therapeutic transplants. These hair disorders include persistent chemotherapy-induced alopecia, persistent radiotherapy-induced alopecia, endocrine therapy –induced alopecia and hirsutism, postsurgery alopecia and localized hypertrichosis, and persistent stem cell transplantation and targeted therapy-induced alopecia.
Source: Journal of the American Academy of Dermatology - April 12, 2018 Category: Dermatology Authors: Azael Freites-Martinez, Jerry Shapiro, Corina van den Hurk, Shari Goldfarb, Joaquin J. Jimenez, Anthony M. Rossi, Ralf Paus, Mario E. Lacouture Tags: Continuing medical education Source Type: research

Hair disorders in patients with cancer
Cytotoxic chemotherapies, molecularly targeted therapies, immunotherapies, radiotherapy, stem cell transplants, and endocrine therapies may lead to hair disorders, including alopecia, hirsutism, hypertrichosis, and pigmentary and textural hair changes. The mechanisms underlying these changes are varied and remain incompletely understood, hampering the development of preventive or therapeutic guidelines. The psychosocial impact of chemotherapy-induced alopecia has been well documented primarily in the oncology literature; however, the effect of other alterations, such as radiation-induced alopecia, hirsutism, and changes in...
Source: Journal of the American Academy of Dermatology - April 12, 2018 Category: Dermatology Authors: Azael Freites-Martinez, Jerry Shapiro, Shari Goldfarb, Julie Nangia, Joaquin J. Jimenez, Ralf Paus, Mario E. Lacouture Tags: Continuing medical education Source Type: research

CME Exam 1: Diarrhea in a Patient Receiving Chemotherapy
Source: Gastroenterology - November 5, 2019 Category: Gastroenterology Tags: Continuing Medical Education (CME)/MOC Activities Source Type: research

Chemotherapy-induced alopecia —A potentially preventable side effect with scalp cooling
To the Editor: We read with interest the continuing medical education article by Freites-Martinez et  al1 regarding hair disorders in cancer survivors. The authors specifically discuss permanent chemotherapy-induced alopecia (CIA) and briefly reviewed the role of scalp cooling toward the prevention of CIA. We would like to focus on additional aspects of scalp cooling therapy to increase dermatolo gists’ awareness of this impactful service. As experts in hair disorders, dermatologists can play an integral role in increasing patient awareness and potential use of this technology.
Source: Journal of the American Academy of Dermatology - September 30, 2019 Category: Dermatology Authors: Taylor Novice, Madison Novice, Jerry Shapiro, Kristen Lo Sicco Tags: JAAD Online Source Type: research

The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradication
Cutaneous T cell lymphomas (CTCLs) are malignancies of skin-trafficking T cells. Patients with advanced CTCL manifest immune dysfunction that predisposes to infection and suppresses the antitumor immune response. Therapies that stimulate immunity have produced superior progression-free survival compared with conventional chemotherapy, reinforcing the importance of addressing the immune deficient state in the care of patients with CTCL. Recent research has better defined the pathogenesis of these immune deficits, explaining the mechanisms of disease progression and revealing potential therapeutic targets.
Source: Journal of the American Academy of Dermatology - December 18, 2020 Category: Dermatology Authors: Joseph S. Durgin, David M. Weiner, Maria Wysocka, Alain H. Rook Tags: Continuing medical education Source Type: research

The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Current and future approaches
In the past few decades, immunotherapy has emerged as an effective therapeutic option for patients with cutaneous T cell lymphoma (CTCL). CTCL is characterized by progressive impairment of multiple arms of the immune system. Immunotherapy targets these deficits to stimulate a more robust antitumor response, thereby both clearing the malignant T cells and repairing the immune dysfunction. By potentiating rather than suppressing the immune system, immunotherapy can result in longer treatment responses than alternatives such as chemotherapy.
Source: Journal of the American Academy of Dermatology - December 18, 2020 Category: Dermatology Authors: David M. Weiner, Joseph S. Durgin, Maria Wysocka, Alain H. Rook Tags: Continuing medical education Source Type: research

Continuing EGFR-TKI treatment in combination with super-selective arterial infusion chemotherapy beyond disease progression for patients with advanced EGFR-mutant non-small cell lung cancer
This study evaluated the efficacy and safety of continuing EGFR-TKI therapy concurrently with arterial infusion chemotherapy in 6 patients (median age 55.9 years) with advanced EGFR-mutant non-small cell lung cancer (NSCLC) who had a locally progressive, centrally located lung lesion after EGFR-TKI therapy. The patients received a super-selective arterial infusion of docetaxel (75 mg/m2) every 28 days concurrently with EGFR-TKI therapy until further progressive disease (PD) or unacceptable adverse effects (AEs) occurred. Treatment outcomes were assessed via progression-free survival (PFS) times (PFS-1: time to PD after ...
Source: Medical Oncology - October 23, 2015 Category: Cancer & Oncology Source Type: research